Full-Time

Scientist – NGS Core Lead

Confirmed live in the last 24 hours

Alltrna

Alltrna

51-200 employees

Develops tRNA therapeutics for disease treatment

Biotechnology

Entry

Cambridge, MA, USA

Category
Computational Biology
Genomics
Biology & Biotech
Requirements
  • PhD in biology or a related discipline with 0-2 years of experience working in biotech or a related industry, or M.S. with 6+ years of relevant experience.
  • Expertise with a variety of Illumina-based NGS methods, including experience with RNA-centric methods and experience developing or implementing custom NGS methods.
  • Demonstrated ability to drive improvements in quality, reproducibility, and/or scale of NGS methods.
  • Experience interpreting NGS data in support of quality assessment, methodology improvement, and experimental troubleshooting.
  • Experience managing or coordinating work of a small team.
  • Demonstrated ability to implement and support technical and operational processes that contribute to the successful execution of scientific research at scale.
  • Excellent communication skills and the ability to clearly explain NGS methods and considerations around their application to team members of diverse backgrounds.
  • Detail-oriented and organized with a strong ability to manage multiple experiments in parallel.
Responsibilities
  • Support company-wide use of tRNA sequencing by coordinating and overseeing work of the NGS core.
  • Contribute to tRNA sequencing work by performing RNA extraction, library preparation, and data review.
  • Drive the continued improvement of tRNA sequencing by identifying and implementing solutions to problems of scale, reproducibility and quality of the method.
  • Coordinate with stakeholders relating to sequencing requests, supporting experimental design, sample submission, tracking experiment status, and troubleshooting unexpected results as needed.
  • Support the transition of sequencing methods from the late stages of their development to establish them as pipeline methods.

Alltrna focuses on developing tRNA therapeutics to treat diseases caused by genetic mutations. Their main product involves engineered tRNAs that can recognize and read stop codons, which are errors in the genetic code that lead to the production of incomplete proteins. By delivering the correct amino acids, these tRNAs help restore the synthesis of full-length proteins, potentially addressing a wide range of diseases linked to nonsense mutations. Unlike other biotech companies, Alltrna is the first to explore the therapeutic potential of tRNA in this way, aiming to unlock new treatment options for patients with specific genetic disorders. The goal of Alltrna is to provide effective therapies that target the root causes of diseases, improving the quality of life for those affected.

Company Stage

Series B

Total Funding

$154.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

-14%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $109 million Series B financing round provides substantial capital to advance their platform and drug candidates, indicating strong investor confidence.
  • Presentations at high-profile conferences like ASGCT and TIDES USA 2024 highlight Alltrna's growing recognition and thought leadership in the biotech community.
  • The appointment of experienced leaders like Chris Henderson as Chief Scientific Officer strengthens their executive team, potentially accelerating innovation and clinical progress.

What critics are saying

  • The novel nature of tRNA therapeutics means there is a high level of scientific and clinical uncertainty, which could delay or derail development efforts.
  • The competitive biotech landscape, especially in genetic therapies, requires continuous innovation to maintain a leading position.

What makes Alltrna unique

  • Alltrna is the first biotech company to decode tRNA biology and leverage it for therapeutic purposes, setting it apart in the biotech landscape.
  • Their focus on treating diseases caused by nonsense mutations through tRNA therapeutics is a unique approach that addresses a significant unmet medical need.
  • The integration of AI/ML tools in their platform enhances their capability to develop diverse programmable molecules, providing a technological edge over competitors.

Help us improve and share your feedback! Did you find this helpful?